Abstract:Rapid developments in clinical research on the hepatitis C virus infection in the last few years have led to the development of direct-acting antivirals, such as sofosbuvir, simeprevir (both of which have been approved in the US and Europe since 2014), and daclatasvir, which was approved in Europe only in 2014. These new drugs generated a change of paradigm from interferon-based therapies, as the former require shorter treatment durations and provide high cure rates with acceptable toxicity. The 65th Ameri… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.